AbbVie to Build Two New Illinois Manufacturing Facilities
What happened
Pharmaceutical company AbbVie announced a $380 million investment to build two new manufacturing facilities in Illinois. The move signals continued corporate confidence in US-based production, particularly in high-value sectors like pharmaceuticals. The investment is part of a broader trend of companies reshoring or expanding domestic manufacturing capacity.
Why it matters
- The new facilities will be located at AbbVie's existing campus in North Chicago, Illinois, and will focus on manufacturing active pharmaceutical ingredients (APIs) for its pipeline of next-generation neuroscience and obesity medications. - Construction is slated to begin in the spring of 2026, with the plants expected to be fully operational by 2029, creating 300 new jobs for engineers, scientists, and manufacturing technicians. - This project is part of a larger trend of reshoring API production; in September 2025, AbbVie began construction on a separate $195 million facility in North Chicago to bring manufacturing of select immunology, oncology, and neuroscience APIs back to the U.S. from Europe and Asia. - The investment is a component of AbbVie's broader commitment to invest $100 billion in U.S. research and development and capital projects over the next decade. - The new facilities will incorporate advanced manufacturing technologies and artificial intelligence, a significant development for internal audit to consider regarding operational efficiency, data integrity, and cybersecurity risks. - This expansion follows a previous one at the same location, for which AbbVie received Economic Development for a Growing Economy (EDGE) tax credits from the state of Illinois. - AbbVie's domestic manufacturing expansion is not limited to Illinois, with recent announcements of a device manufacturing facility acquisition in Arizona and significant investments at its site in Massachusetts. - The move mirrors similar domestic investment pledges from other pharmaceutical giants, including Johnson & Johnson's $55 billion commitment and AstraZeneca's $50 billion allocation to U.S. manufacturing and R&D.
Key numbers
- Pharmaceutical company AbbVie announced a $380 million investment to build two new manufacturing facilities in Illinois.
- Construction is slated to begin in the spring of 2026, with the plants expected to be fully operational by 2029, creating 300 new jobs for engineers, scientists, and manufacturing technicians.
- This project is part of a larger trend of reshoring API production; in September 2025, AbbVie began construction on a separate $195 million facility in North Chicago to bring manufacturing of select immunology, oncology, and neuroscience APIs back to the U.S.
- The investment is a component of AbbVie's broader commitment to invest $100 billion in U.S.
What happens next
- The new facilities will be located at AbbVie's existing campus in North Chicago, Illinois, and will focus on manufacturing active pharmaceutical ingredients (APIs) for its pipeline of next-generation neuroscience and obesity medications.
- Construction is slated to begin in the spring of 2026, with the plants expected to be fully operational by 2029, creating 300 new jobs for engineers, scientists, and manufacturing technicians.
- research and development and capital projects over the next decade.
Quick answers
What happened in AbbVie to Build Two New Illinois Manufacturing Facilities?
Pharmaceutical company AbbVie announced a $380 million investment to build two new manufacturing facilities in Illinois. The move signals continued corporate confidence in US-based production, particularly in high-value sectors like pharmaceuticals. The investment is part of a broader trend of companies reshoring or expanding domestic manufacturing capacity.
Why does AbbVie to Build Two New Illinois Manufacturing Facilities matter?
The new facilities will be located at AbbVie's existing campus in North Chicago, Illinois, and will focus on manufacturing active pharmaceutical ingredients (APIs) for its pipeline of next-generation neuroscience and obesity medications. Construction is slated to begin in the spring of 2026, with the plants expected to be fully operational by 2029, creating 300 new jobs for engineers, scientists, and manufacturing technicians. This project is part of a larger trend of reshoring API production; in September 2025, AbbVie began construction on a separate $195 million facility in North Chicago to bring manufacturing of select immunology, oncology, and neuroscience APIs back to the U.S. from Europe and Asia. The investment is a component of AbbVie's broader commitment to invest $100 billion in U.S. research and development and capital projects over the next decade. The new facilities will incorporate advanced manufacturing technologies and artificial intelligence, a significant development for internal audit to consider regarding operational efficiency, data integrity, and cybersecurity risks. This expansion follows a previous one at the same location, for which AbbVie received Economic Development for a Growing Economy (EDGE) tax credits from the state of Illinois. AbbVie's domestic manufacturing expansion is not limited to Illinois, with recent announcements of a device manufacturing facility acquisition in Arizona and significant investments at its site in Massachusetts. The move mirrors similar domestic investment pledges from other pharmaceutical giants, including Johnson & Johnson's $55 billion commitment and AstraZeneca's $50 billion allocation to U.S. manufacturing and R&D.
